Abstract:Yaling Lou, 1 Xuting Xu, 2 Ronghua Wang, 1 Danfeng Yao 3 1 Department of Clinical Pharmacy, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 2 Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 3 Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, Huzhou, People's Republic of China Correspondence: Danfeng Yao, Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, No. 2, East Street, Wuxing District, Huzhou, 313000, People's Republic of China, Email Background: The mechanism of Chemotherapy-induced neuropathic pain (NP) remains obscure. This study was aimed to uncover the key genes as well as protein networks that contribute to Oxaliplatin-induced NP. Material/Methods: Oxaliplatin frequently results in a type of Chemotherapy-induced NP that is marked by heightened sensitivity to mechanical and cold stimuli, which can lead to intolerance and discontinuation of medication. We investigated whether these different etiologies lead to similar pathological outcomes by targeting shared genetic targets or signaling pathways. Gene expression data were obtained from the Gene Expression Comprehensive Database (GEO) for GSE38038 (representing differential expression in the spinal nerve ligation model rats) and GSE126773 (representing differential expression among the Oxaliplatin-induced NP model rats). Differential gene expression analysis was performed using GEO2R. Results: Protein-protein interaction (PPI) analysis identified 260 co-differentially expressed genes (co-DEGs). Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed three shared pathways involved in both models: Kaposi sarcoma-associated herpesvirus (KSHV) infection, Epstein-Barr virus (EBV) infection, and AGE-RAGE signaling pathway in diabetic complications. Further bioinformatics analysis highlighted eight significantly up-regulated genes in the NP group: Mapk14, Icam1, Cd44, IL6, Cxcr4, Stat1, Casp3 and Fgf2. Our results suggest that immune dysfunction, inflammation-related factors or regulating inflammation factors may also be related to Oxaliplatin-induced NP. Additionally, we analyzed a dataset (GSE145222) involving chronic compression of DRGs (CCD) and control groups. CCD model is a classic model for studying NP. We assessed these hub genes' expression levels. In contrast with the control groups, the hub genes were up-regulated in CCD groups, the difference was statistically significant, except Stat1. Conclusion: Our research significantly contributes to elucidating the mechanisms underlying the occurrence as well as the progression of Oxaliplatin-induced NP. We have identified crucial genes and signaling pathways associated with this condition. Keywords: neuropathic pain, oxaliplatin, spinal dorsal horn, bioinformatics, differentially expressed genes, hub genes Chemotherapy-induced neuropathic pain (CINP) is a progressive, persistent, and challenging disease characterized by pain, numbness, tingling sensation, and sensitivity to cold. It affects about 50–90% of individuals undergoing chemotherapy treatment. 1 CIPN is mainly induced by first-line chemotherapy drugs such as oxaliplatin, paclitaxel, and vinblastine. With the accumulation of chemotherapy drug toxicity, peripheral neuropathological symptoms become increasingly severe, compelling patients to reduce the chemotherapy drug dosages, shorten the chemotherapy cycle, or even discontinue medication, ultimately impacting patient survival rates. Chemotherapy-induced neuropathic pain (CINP) remains a therapeutic challenge with no effective drugs and treatments currently available. Oxaliplatin is a widely used chemotherapy-drug for the treatment of colorectal and advanced ovarian cancer. 2 However, one of the major side effects associated with oxaliplatin treatment is the development of neuropathic pain (NP). This condition is characterized by severe and painful peripheral neuropathy, which can often lead to dose reduction or early discontinuation of chemotherapy. 3,4 Despite its clinical significance, the exact mechanism underlying Oxaliplatin-induced neurotoxicity and the subsequent development of NP remains unclear. Inflammation of the dorsal root ganglions (DRGs) is the pivotal physiological basis for the occurrence of NP. During the process of pain generation, the DGRs serve as the primary neuron of pain input in the pain mechanism. So the DGRs are considered to be key participants within the pathogenesis that lead to NP.<s -Abstract Truncated-

Spinal pituitary adenylate cyclase-activating polypeptide and PAC1 receptor signaling system is involved in the oxaliplatin-induced acute cold allodynia in mice

Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity

RgIA4 Prevention of Acute Oxaliplatin-Induced Cold Allodynia Requires α9-Containing Nicotinic Acetylcholine Receptors and CD3+ T-Cells

L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats

Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy

The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin

Identification of Key Genes and Pathways in Oxaliplatin-Induced Neuropathic Pain Through Bioinformatic Analysis

Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms

Hyperbaric Oxygen Therapy Alleviates Paclitaxel-Induced Peripheral Neuropathy Involving Suppressing TLR4-MyD88-NF-κB Signaling Pathway

Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice

Inducible co-stimulatory molecule (ICOS) alleviates paclitaxel-induced neuropathic pain via an IL-10-mediated mechanism in female mice

αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model

Contribution of T‐type calcium channel isoforms to cold and mechanical sensitivity in naïve and oxaliplatin‐treated mice of both sexes

NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy

Endothelial glycocalyx in the peripheral capillaries is injured under oxaliplatin-induced neuropathy

The G2A receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity

Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants

In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor

Monoclonal Antibody Targeting CGRP Relieves Cisplatin-Induced Neuropathic Pain by Attenuating Neuroinflammation

Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

Chemotherapy-induced peripheral neuropathy is promoted by enhanced spinal insulin-like growth factor-1 levels via astrocyte-dependent mechanisms